MGNX Stock Price, Chart, Stats & News
MacroGenics, Inc. (MGNX) does not currently pay a dividend.
MGNX chart
Fundamentals
Gross margin | 71.12% |
Operating margin | -48.72% |
Pretax margin | -50.36% |
Net margin | -49.91% |
Effective tax rate | 0.89% |
ROA | -29.05% |
ROE | -120.20% |
D/E | 1.92x |
Interest coverage ratio | -8.56x |
MGNX valuation
P/E | – |
P/S | 1.25x |
P/B | 3.33x |
P/CF | -2.28x |
P/FCF | -2.24x |
P/OCF | -2.28x |
PEG | -0.99x |
EV multiple | -2.08x |
About
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
Similar securities
Based on sector and market capitalization
